Skip to main content

Rhinitis, Allergic

6
Pipeline Programs
5
Companies
8
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
loratadine + pseudoephedrine sulfatePhase 41 trial
Chlorpheniramine maleatePhase 21 trial
Active Trials
NCT02722083Terminated1Est. Jul 2016
NCT03443843Completed82Est. May 2018
Inmunotek
InmunotekSpain - Madrid
3 programs
3
10,000 MG01 + 10,000 T517Phase 31 trial
10,000 MG01 +10,000 T521Phase 31 trial
10,000 MM09Phase 31 trial
Active Trials
NCT04891237Recruiting180Est. Jan 2027
NCT04898283Recruiting180Est. Oct 2026
NCT04435990Recruiting150Est. Dec 2026
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
HAL-MRE1Phase 11 trial
Pollinex Quattro with tree- and grass pollen extracts and their mixturesN/A1 trial
Active Trials
NCT04389034Completed113Est. Oct 2020
NCT03758456Completed45Est. May 2019
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Ganciclovir Oral CapsuleN/A1 trial
Active Trials
NCT06436534Recruiting50Est. May 2026
Hal Allergy
Hal AllergyNetherlands - Leiden
1 program
HAL-MRE1PHASE_1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bayerloratadine + pseudoephedrine sulfate
Inmunotek10,000 MG01 + 10,000 T517
Inmunotek10,000 MG01 +10,000 T521
Inmunotek10,000 MM09
BayerChlorpheniramine maleate
Allergy TherapeuticsHAL-MRE1
UNION therapeuticsGanciclovir Oral Capsule
Allergy TherapeuticsPollinex Quattro with tree- and grass pollen extracts and their mixtures

Clinical Trials (8)

Total enrollment: 801 patients across 8 trials

NCT03443843Bayerloratadine + pseudoephedrine sulfate

A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure

Start: Feb 2018Est. completion: May 201882 patients
Phase 4Completed
NCT04891237Inmunotek10,000 MG01 + 10,000 T517

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

Start: Jun 2021Est. completion: Jan 2027180 patients
Phase 3Recruiting
NCT04898283Inmunotek10,000 MG01 +10,000 T521

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

Start: May 2021Est. completion: Oct 2026180 patients
Phase 3Recruiting
NCT04435990Inmunotek10,000 MM09

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

Start: Oct 2020Est. completion: Dec 2026150 patients
Phase 3Recruiting
NCT02722083BayerChlorpheniramine maleate

Exploratory Study for Allergy Relief Onset

Start: May 2016Est. completion: Jul 20161 patients
Phase 2Terminated
NCT03758456Allergy TherapeuticsHAL-MRE1

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

Start: Nov 2018Est. completion: May 201945 patients
Phase 1Completed
NCT06436534UNION therapeuticsGanciclovir Oral Capsule

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Start: May 2024Est. completion: May 202650 patients
N/ARecruiting
NCT04389034Allergy TherapeuticsPollinex Quattro with tree- and grass pollen extracts and their mixtures

Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (IgE) Levels

Start: Apr 2020Est. completion: Oct 2020113 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 801 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.